Hepatitis B virus does not take antiviral drugs Viral load can be reduced in patients in the immune-clearance phase, but not in patients in the immune-tolerance phase. The natural history of chronic HBV infection can generally be divided into four phases based on the natural course of the disease, i.e., the immune tolerance phase (chronic HBV carrier state), the immune clearance phase (HBeAg-positive CHB), the immune control phase (inactive HBsAg carrier state), and the reactivation phase (HBeAg-negative CHB). Spontaneous HBeAg seroconversion may occur in patients in the immune-clearance phase, with an annual incidence of approximately 2% to 15%.After HBeAg seroconversion, HBsAg clearance occurs in approximately 0.5% to 1.0% of patients each year. In patients with immune tolerance, HBV-specific T cells are susceptible to apoptosis, significantly reduced in both cytokine production and proliferative capacity, and functional exhaustion, which may be the cause of persistent HBV infection and immune tolerance, and the virus will not be cleared. Hepatitis B virus patients should be followed up regularly for treatment in specialized outpatient clinics.